MREO vs ATON โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MREO Captures Institutional Edge (3โ1 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Mereo BioPharma Group plc American Depositary Shares (MREO) driven by superior Valuation, Momentum & Technical, Options & Structure while ATON counters with relative strength in Growth & Margin. Fundamentally, MREO trades at 113.9x Forward P/E with -3702.5% operating margin (+0.0% YoY revenue) versus ATON at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MREO sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against ATON sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MREO | ATON | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $48.7M | $7.5M | Larger Scale | MREO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | 113.9x | N/M | Lower Multiple | MREO |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | -3702.5% | 0.0% | Higher Margin | ATON |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -76.6% | -311.0% | Higher ROE | MREO |
| 52-Week Range Position Momentum | 5% ($0โ$2) | 0% ($0โ$14) | Stronger Trend | MREO |
| Beta / 30D Volatility Risk Regime | 1.09ฮฒ ยท 48% Vol | 1.90ฮฒ ยท 65% Vol | Lower Realized Risk | MREO |
| Unified Institutional Score Composite Signal | 46.9 / 100 (HOLD) | 45.1 / 100 (HOLD) | Higher Composite | MREO |